Financials in USD. Standardized financial statements.
A compact view of how Dermapharm Holding SE turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $1.16B | $1.18B | $1.15B | $1.02B | $942.91M | $793.83M | $700.88M | $572.42M | $467.12M | $444.48M |
| Revenue Growth? | -1.4% | +2.6% | +12.3% | +8.7% | +18.8% | +13.3% | +22.4% | +22.5% | +5.1% | 0.0% |
| Cost of Revenue? | $772.98M | $413.70M | $446.60M | $363.94M | $322.22M | $330.35M | $317.16M | $272.66M | $245.64M | $243.45M |
| Gross Profit? | $391.56M | $767.07M | $704.14M | $660.83M | $620.69M | $463.48M | $383.72M | $299.76M | $221.47M | $201.03M |
| Gross Margin? | +33.6% | +65.0% | +61.2% | +64.5% | +65.8% | +58.4% | +54.7% | +52.4% | +47.4% | +45.2% |
| Operating Expenses? | $169.90M | $550.14M | $521.25M | $418.78M | $333.65M | $318.21M | $263.98M | $190.90M | $130.66M | $114.93M |
| Operating Income? | $221.66M | $216.93M | $182.89M | $243.69M | $298.47M | $136.85M | $119.51M | $107.51M | $92.12M | $86.79M |
| EBITDA? | $314.19M | $320.91M | $262.74M | $323.54M | $356.97M | $182.07M | $168.01M | $140.42M | $111.65M | $105.58M |
| Income Before Tax | $183.44M | $172.00M | $106.00M | $216.30M | $292.98M | $125.28M | $110.07M | $104.24M | $88.03M | $82.87M |
| Income Tax Expense | $52.14M | $60.27M | $45.46M | $83.68M | $84.07M | $39.36M | $32.25M | $29.01M | $10.29M | $5.87M |
| Net Income? | $132.36M | $113.79M | $62.37M | $134.24M | $209.58M | $85.83M | $77.20M | $75.32M | $77.74M | $16.82M |
| EPS? | $2.46 | $2.11 | $1.16 | $2.49 | $3.89 | $1.59 | $1.43 | $1.41 | $1.56 | $1.54 |
| Diluted EPS? | $2.46 | $2.11 | $1.16 | $2.49 | $3.89 | $1.59 | $1.43 | $1.41 | $1.56 | $1.43 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality